Intervontions of Interest:
- etranacogene dezaparvovec (CSL Behring)
- valoctocogene roxaparvovec (Roctavian ™; BioMarin)
For questions, please contact Monica Frederick, Program Associate, at mfrederick@icer.org.
View the Key Stakeholder List.
Hemophilia A and B
An assessment of gene therapies, including etranacogene dezaparvovec and valoctocogene roxaparvovec
Public Meeting
November 2022
Assessment Status
Open
Upcoming Milestone
Revised Scoping DocumentView
Main Review
November 18, 2022
CTAF
The CTAF’s 2022 public meeting on gene therapies for hemophilia.
Public Comment Period
See Full Timeline
05/05/2022 - 05/25/2022
Draft Scoping Document Public Comments
Related Assessments & Policy Papers.
Hemophilia A
Mar 2018Hemophilia A
Oct 2020
05/05/2022 - 05/25/2022
Draft Scoping Document Public Comments
06/06/2022
Revised Scoping Document
06/13/2022
Research Protocol
07/28/2022
Model Analysis Plan
09/13/2022 - 10/11/2022
Public Comments on Draft Evidence Report
11/02/2022
Evidence Report
11/18/2022
Evidence Presentation
12/19/2022
Public Comments
OpenView
Closed